Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 5/20 | 0.83 |
| ▸ | ORAI1 | Q96D31 | 5/20 | 0.83 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ESRRG | P62508 | 5/20 | 0.50 |
| ▸ | ESR1 | P03372 | 3/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | IL2 | P60568 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721455 | 0.91 | STIM1 (1.00) | STIM1ORAI1NPC1RAB9ATP53 | |
| SCHEMBL721821 | 0.89 | STIM1 (0.71) | STIM1ORAI1NPC1RAB9ATP53 | |
| SCHEMBL29642099 | 0.89 | STIM1 (0.71) | STIM1ORAI1NPC1RAB9ATP53 | |
| SCHEMBL720890 | 0.86 | STIM1 (0.62) | STIM1ORAI1NPC1RAB9ATP53 | |
| SCHEMBL720884 | 0.80 | STIM1 (0.80) | STIM1ORAI1NPC1RAB9AESRRG | |
| SCHEMBL10201120 | 0.78 | STIM1 (0.53) | STIM1ORAI1NPC1RAB9ATP53 | |
| SCHEMBL29642074 | 0.78 | STIM1 (0.53) | STIM1ORAI1NPC1RAB9ATP53 | |
| SCHEMBL720496 | 0.75 | STIM1 (0.64) | STIM1ORAI1NPC1RAB9ATP53 | |
| SCHEMBL10201083 | 0.74 | STIM1 (0.75) | STIM1ORAI1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL724410 | 0.70 | STIM1 (0.47) | STIM1ORAI1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336738-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20150344469-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-12-03 | — | — | US | disclosed |
| US-20150344469-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-12-03 | — | — | US | disclosed |
| US-9079891-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079891-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20120053210-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053210-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2012027710-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336738-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885NPC1 262/4885 |
| US-20150344469-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885NPC1 262/4885 |
| US-20120053210-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885NPC1 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.